Teva Pharmaceutical Industries (NYSE:TEVA) is a global pharmaceutical company headquartered in Petah Tikva, Israel, with operations spanning North America, Europe, Latin America, Asia Pacific and the Middle East. The company is a leading provider of generic medicines, offering more than 1,600 active pharmaceutical ingredients and over 3,500 generic dosage forms. Teva’s broad portfolio addresses diverse therapeutic areas, including central nervous system disorders, oncology, respiratory conditions and women’s health.
Founded in 1901 as Salomon, Levin and Elstein Ltd., Teva built its reputation on the production of affordable, high-quality generics. Over the decades, the company expanded through strategic acquisitions, including the generic business of Ivax Corporation in 2005 and the acquisition of Allergan’s global generic operations in 2016. These moves helped Teva establish one of the world’s largest generic platforms by volume.
In addition to generics, Teva develops and markets specialty pharmaceuticals. Its branded portfolio includes treatments for multiple sclerosis, such as Copaxone, as well as therapies for migraine prevention and chronic pain management. The company maintains research and development centers in Israel, the United States and Europe, focusing on innovations in biologics and complex generics.
Teva employs more than 35,000 people worldwide and is led by President and Chief Executive Officer Kåre Schultz. With a commitment to expanding patient access to medicine, the company combines its global manufacturing footprint with continuous investment in R&D to address evolving healthcare needs across more than 100 markets.
